Erik Boldt is an Advanced R&D Scientist at Honeywell’s Buffalo Research Lab located in Buffalo, New York, where he leads the development of HFO-1234ze(E) in pharmaceutical applications. His current research focuses on formulation development, material compatibility, performance, and stability of metered dose inhalers using HFO-1234ze(E) as propellant. Erik received his Master’s degree in Medicinal Chemistry from the University at Buffalo and has been working in the biotech industry for over 5 years, including in drug discovery, large-scale manufacturing, and clinical development.
